loader
Please Wait
Applying Filters...
Close
4

Polpharma European CDMO Partner & API Manufacturer since 1951 Polpharma European CDMO Partner & API Manufacturer since 1951

X

Information, Expiry & Status of FDA Orange Book Patents covering Linagliptin

Client Email Product
Menu
Filters Filter
Cross PopUp
FILTER :

filter

01 BOEHRINGER INGELHEIM (247)

filter

01 10022379*PED (5)

02 10034877*PED (1)

03 10258637*PED (6)

04 10973827*PED (3)

05 11033552*PED (3)

06 11090323*PED (6)

07 7407955 (12)

08 7407955*PED (12)

09 7579449 (6)

10 7579449*PED (6)

11 7713938 (6)

12 7713938*PED (6)

13 8551957 (6)

14 8551957*PED (6)

15 8673927 (8)

16 8673927*PED (8)

17 8846695 (4)

18 8846695*PED (4)

19 8853156 (1)

20 8853156*PED (1)

21 8883805 (12)

22 8883805*PED (12)

23 9155705 (9)

24 9155705*PED (5)

25 9173859 (4)

26 9173859*PED (2)

27 9415016 (9)

28 9486526 (1)

29 9555001 (4)

30 9949998 (6)

31 10022379 (9)

32 10034877 (1)

33 10258637 (6)

34 10406172 (4)

35 10596120 (8)

36 10973827 (3)

37 11033552 (3)

38 11090323 (6)

39 11564886 (3)

40 11833166 (12)

41 11911388 (6)

42 9415016*PED (5)

43 9486526*PED (1)

44 9555001*PED (2)

45 9949998*PED (4)

filter

01 Y (24)

02 Blank (223)

filter

01 Y (88)

02 Blank (159)

filter

01 2025-05-02 (12)

02 2025-11-02 (12)

03 2025-11-26 (12)

04 2026-05-26 (12)

05 2027-04-15 (6)

06 2027-05-04 (15)

07 2027-10-15 (6)

08 2027-11-04 (13)

09 2028-08-01 (6)

10 2029-02-01 (6)

11 2029-04-02 (21)

12 2029-08-05 (2)

13 2029-10-02 (13)

14 2029-10-14 (6)

15 2030-02-05 (2)

16 2030-04-10 (6)

17 2030-04-14 (6)

18 2030-05-21 (9)

19 2030-06-04 (4)

20 2030-06-15 (4)

21 2030-11-21 (5)

22 2030-12-04 (4)

23 2031-03-05 (1)

24 2031-09-05 (1)

25 2032-03-07 (11)

26 2033-03-06 (4)

27 2033-09-06 (2)

28 2034-04-03 (24)

29 2034-06-11 (6)

30 2034-10-03 (12)

31 2034-12-11 (4)

URL Supplier Web Content
9173859
Y
2027-05-04
U-1772
Y
206073
METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
1
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
8853156
Y
2031-03-05
U-1642
201280
METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINI
1
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
8673927
2027-05-04
U-1503
Y
201281
METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
1
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
8673927
2027-05-04
U-1503
Y
201281
METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
3
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
8673927
2027-05-04
U-1503
Y
201280
METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
1
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
9173859
Y
2027-05-04
U-1503
Y
208026
METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
9555001
Y
2033-03-06
U-1967
208026
1
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
9555001
Y
2033-03-06
U-1968
208026
2
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content